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Abstract  
AIM: The study aim is to evaluate the cost-effectiveness of thrombolytic treatment in acute MI 
comparing with anticoagulants therapy and between each other thrombolytic (SK, r-Pa). 
MATERIAL AND METHODS: We used a prospective registry of all patients admitted for acute 
myocardial infarction in intensive care units in Tirana. The average drugs cost was calculated for 
the hospitalization period in Albanian money (ALL). Survival and life quality were estimated by 
phone contact 1 year after acute MI.  
RESULTS: Anticoagulant group cost is 23865.3 ALL (170.5€), SK group cost is 54148.63 ALL 
(386.7€), r-Pa group has a cost of 92184.90 ALL (658.5€). In the group treated with SK the hospital 
survival is 100%, while in the control group 88.8%. Reteplase group has a lower period of stay in 
hospital than SK group 13.04 days vs. 17.97 days, mean age in group treated with r-Pa is 64.29 ± 
10.03 approximate with anticoagulant group mean age 64.17 ± 11.08; differ significantly with SK 
group mean age 56.75 ± 10.04. Survival after 1 year was 96.4% for r-Pa and 96.9% SK.  
CONCLUSIONS: SK and r-Pa are successful thrombolytics with high effectiveness. It is gained a 
higher survival with the thrombolytic treatments. Reteplase is well tolerated in older patients than 
SK, is easier to apply than Streptokinase, but has higher cost. 
 
 
 
 
Introduction 
 
Acute myocardial infarction (AMI) remains 
one of the major causes of morbidity and mortality in 
the world, caused by the closure of coronary arteries 
due to thrombus. Deaths with coronary heart disease 
cover about 7 million people (about 30% of mortality, 
according to the WHO). In Europe around 2 million 
people die annually from cardiovascular diseases. 
From literature also it is noted that AMI appears 
almost twice more in men than in women (10% vs. 
6%) [1]. The purpose of the thrombolytic therapy is the 
reduction of mortality after myocardial infarction and 
improvement of life quality to patients with acute MI. 
Thrombolytic therapy has been a major breakthrough 
in the management of acute myocardial infarction. 
This treatment works by merging thrombus formed in 
arteries and reaching a circulation of blood to the 
arteries in order to avoid death and improve survival 
[2]. Thrombolytic drugs are most effective if 
administered immediately after the determination of 
first symptoms of the AMI. The benefit of 
thrombolytics use is higher when they apply within the 
first 6-12 hours of symptoms [3]. These drugs are 
usually used in combination with anticoagulants such 
as heparin, fraksiparina, calciparina, dalteparina, 
enoxaparina [4]. 
Streptokinase belongs to the first generation 
thrombolytic group. SK disadvantage is that it has little 
specificity for fibrin, increases the risk of allergic 
reactions and it has a low biological half-life [5]. 
Reteplase is the newest thrombolytic agent 
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(generate III), used in the treatment of acute MI, with 
longer biological half-life of advantage [6]. 
However a numerous studies (GUSTO, 
INJECT) showed no significant changes play 
regarding hospital survival between these 
thrombolytics used to treat acute MI. [7, 8]. Also in 
others studies like RAPID-II and GUSTO-III is proven 
effectiveness of these thrombolytics used and results 
after a period of one year showed no significant 
differences between the two treatments [9, 11]. 
The purpose of this study is: - to compare 
survival between the two thrombolytics; Reteplase vs. 
streptokinase; - to compare survival between groups 
who have used anticoagulants vs thrombolytic 
treatment of AMI; and - to estimate the cost of 
treatment of acute myocardial infarction, respectively 
in each group. 
The aim of this study is to evaluate 
thrombolytic cost - effectiveness therapy in acute 
myocardial infarction in intensive care hospital in 
Tirana as a better choice to reduce mortality, 
calculation of the hospital treatment cost and finally 
finding out the cost- effective treatment. This cost- 
effectiveness analyses will be a novel solution for 
hospital treatments here in Albanian hospitals where 
cardiology intensive care is offered. 
 
 
Material and Methods  
 
We used a prospective registry of all patients 
admitted for acute myocardial infarction in intensive 
care units in Tirana. The study included 332 patients 
with acute myocardial infarction (MI), which were in- 
hospital treatment, at Intensive Care Clinic of the 
University Hospital Centre, “Mother Theresa” Tirana, 
in the period 2010-2012. 120 patients (28females and 
92males) received thrombolytic therapy (streptokinase 
or reteplase), the rest served as control group (212 
patients; 53 females and 159 males) and received 
standard therapy with anticoagulants: fraxiparine, 
Plavix, aspirin, heparin. The patients in the control 
group were treated with standard anticoagulants 
therapy in 2010-2011, because there no thrombolytic 
drug in our hospital during this period of time or it was 
in small amounts. These patients were diagnosed as 
the same as the thrombolytic group with AMI. In the 
group of patients receiving r-PA took part 56 patients. 
64 patients were part of SK treatment. We compared 
the thrombolytic treatment vs. anticoagulant and also 
SK with r-Pa. 
It is calculated the average drugs cost for 
each patient for the period of stay in hospital. 
Survivals, mortality and quality of life were defined 
through interviews with telephone contact to patients 1 
year after the acute MI. 
Quantitative variables continuous and discrete 
were used, as well as qualitative variables. 
Continuous variables were presented in the average 
value and standard deviation, and discrete variables 
in absolute value and percentage. It is used student 
test for significant differences in hospital stay and the 
confidence interval for comparisons between drugs in 
the two groups. To compare the situation of patients 
after treatment was used Hi-Square test. There were 
considered significant values of P ≤ 0.05 (P ≤ 5%) 
Data analysis was performed with SPSS 
statistical package, version 18. 
 
Results 
The study enrolled a total of 388 patients with 
Acute Myocardial Infarction that were hospitalized at 
Intensive Care Clinic, in the period 2009-2012.After 
the data were collected; the results were presented 
with Tables and Figures. 
Table 1: Summary data of each group 
Variables  Total population 
n= 332 
Gr. with SK 
n=64 
Gr. With r-
Pa 
n=56 
Gr. With 
anticoag 
n=212 
p-value 
Age (in years)  56.03 64.29 64.17 0.001 
Gender 
M 
f 
  
48 
16 
 
44 
12 
 
159 
53 
 
Survival  96.9% 96.4% 88.8% <0.005 
 
Table 1 shows that control group has a mean 
age greater than thrombolytic group (64.2 ± 11.8 vs. 
56.7 ± 10.3).There are significant difference between 
two groups p ≤ 0.005. In this table is compared control 
group with thrombolytic group taken together as one. 
Table 2: Presentation of age in the (SK+ r-Pa) group and 
control group 
          Std. Error  
  Group N Mean Std. Deviation  Mean 
Age-year  SK and r-Pa 120 56.7479 10.03994 0.92036 
  Anticoagulants  212 64.1745 11.08745 0.76149 
 
It is showed that the largest number of cases 
with acute MI is concentrated in the age group 60-70 
years. Acute MI is less common in extreme ages 28-
34 and 80-85 years old (Fig.1). 
 
Figure 1: Number of cases with AMI by age 
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Figure 2: Number of patients according the gender and groups 
 
Figure 2 shows clearly that acute MI affects 
males more than females. There are more males with 
acute MI in both groups than females. 
 
Table 3: It shows the average age in thrombolytic groups 
  Medicine Nr of cases Average SD SE t Df Value of p 
Age  
Reteplase  56 64.29 10.03 1.89 3 58 0.001 
Streptokinase  64 56.03 8.71 1.54 
   
 
There were compared the thrombolytics 
between each other (tab.3). The average age in the 
group with r-Pa (64.29 ± 3.10) is higher than the 
average age of the SK group (56.75 ± 4.10), P = 
0.001. This shows that reteplase is tolerable even in 
higher ages. 
Table 4: Survival comparison between each group period at the 
end of the hospital treatment 
Hospital survival in 
r-Pa, SK and 
anticoagulant groups 
  
  
Total (N=332) Reteplase  
(N=56) 
Streptokinase 
(N=64) 
Anticoagulant 
N=212 
Patients 
after 
treatment 
Dead 
1 1 10 12 
3.6% 3.1% 4.7 3.01% 
Improved  
55 63 202 320 
96.4% 96.9% 95.3% 96.7% 
 
Table 4 shows hospital survival in each 
thrombolytic group (r-Pa), (SK) and anticoagulant 
group. There is only one dead patient at SK group and 
so it is at r-Pa, while at anticoagulant there are 10 
dead patients. Survival rate at r-Pa group is 96.4%, at 
SK group is 96.9%, at anticoagulant Group 95.3% 
Table 5: Comparison between hospital stay periods of time in 
each group 
 
Treatment 
Nr of 
cases 
Mean SD SE t Df Value p 
Hospital 
stay 
period 
Reteplase 56 13.04 5.92 1.12 -3 58 0.010 
Streptokinase 64 17.97 8.14 1.44 
   
 Anticoagulant 120 16.02 8.3 1.20    
 
The group treated with r-Pa has an average 
stay 13.04 days/patient in the hospital with SD 5.92. 
The group treated with SK has an average stay17.97 
days/patient in hospital and SD 8.14 and 
anticoagulant. Group has an average hospital stay of 
16.02 days, where P=0.01. 
Table 6 shows the situation 1 year after the 
treatment, where there are no significant differences 
between the two treatments with thrombolytics. 
Table 6: Comparison after one year of acute MI treatment 
 
Treatment 
Total Reteplase 
(N=56) 
Streptokinase 
(N=64) 
Situation 1 year 
after treatment 
Dead 1 (3.6) 1 (3.2) 2 (3.3) 
Worse  0 (0.0) 4 (6.4) 4 (3.3) 
Good 41 (71.4) 35 (54.8) 76 (61.7) 
Very good 14 (25.0) 24 (38.6) 38 (31.7) 
 
 The cost in r-Pa group is 658.5€, in SK group 
386.8€ and in anticoagulant group it is 207.4€ 
Treatment with r-Pa has a cost of 38036.27 ALL 
(271.7 €) higher than treatment with SK, and 451.1€, 
P = 0.001, otherwise anticoagulant group has a lower 
treatment cost than both other groups.  
Table 7: It shows the treatment cost in each group 
 
Treatment 
Nr of 
cases 
Mean SD SE t D f 
Value 
p 
Total 
cost 
Reteplase 56 92184.90 11191.19 2114.94 12 58 <0.001 
Streptokinase 64 54148.63 13693.78 2420.74 
   
 Anticoagulant 212 29030.85 18066.39 2695.34    
 
 
Discussions  
 
Acute Myocardial Infarction is shown in males 
people more than in females [10]. In our study 75.6% 
of cases with AMI are males and only24.4% are 
females. The available data from clinical trials have 
shown that reteplase acts faster than SK in patients 
with acute MI [12]. In our study we assessed both 
thrombolytic used, and the group with anticoagulants. 
The thrombolytic therapy is more effective than 
anticoagulants therapy for AMI [2]. Assessing in- 
hospital mortality in all groups, we evaluated the 
advantages of thrombolytics compared with standard 
anticoagulant therapy. The mortality rate was 3.6% in 
r-Pa group, 3.1% in SK group and 4.7% in 
anticoagulant group. From numerous studies it was 
observed that between two thrombolytics SK and r-PA 
(Inject study) [13] there were no significant 
differences, so the hospital survival in our study is 
approximate 96.4% in the group with r-Pa and 96.9% 
in the group with SK. While in the group treated with 
anticoagulants there are 10 cases of death and 
survival is 95.3%.  
From another study has found that r-Pa has a 
much higher treatment cost than SK (GUSTO-I study) 
[14]. Likewise, in our study r-Pa has higher costs than 
SK and anticoagulants (€ 685.5 vs. 386.8 €, 207.4€). 
The high treatment cost of reteplase has to be 
evaluated in further studies in which must be defined 
the efficiency and the cost (QALY/life saved). Even 
though there are not direct comparing studies 
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between reteplase and streptokinase regarding 
survival rate one year after thrombolytic treatment of 
acute MI [16], in this study it is shown the equivalence 
in survival and no significant differences between two 
thrombolytics. 
In conclusion, Streptokinase and Reteplase 
are successful thrombolytics in treatment of acute 
myocardial infarction, with high efficiency comparing 
with anticoagulants therapy. It is obtained a greater 
survival with thrombolytic treatment compared with the 
control group treated with anticoagulants’ therapy. 
Reteplase is more acceptable to older ages than SK. 
Reteplase is more easily applicable than SK. r-Pa has 
a higher treatment cost then SK, however, it is an 
added value in the range of thrombolytics used in the 
treatment of AMI. 
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